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Abstract
Purpose of Review Aging is associated with an increased prevalence of both cancer and heart disease. The progression of aortic
valve calcification to aortic stenosis may be accelerated by both cardiovascular risk factors and cancer treatments, such as
radiotherapy with mediastinal involvement. Symptomatic aortic stenosis is occasionally diagnosed in cancer patients undergoing
cardiovascular evaluation; likewise, cancer is often recognized during assessment preceding aortic valve interventions. In these
complex cases, physicians face difficult treatment decisions. Due to a myriad of clinical presentations of cancer and valve disease,
specific guidelines for this patient population are not currently in place. Management is currently based on clinical judgment, on
an individual basis.
Recent Findings Patients with cancer in remission or with a favorable prognosis should be treated according to current cardio-
vascular guidelines. In these patients, aortic valve replacement can be performed either by surgery or transcatheter. Significant
challenges arise in patients with active cancer, especially those receiving anti-cancer treatment. Recent data suggests that these
patients can be offered aortic valve replacement, with a trend of favoring the transcatheter route in order tominimize perioperative
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risk and complications associated with major surgery. Patients with advanced cancer and severe aortic stenosis should be offered
palliative care and can benefit from aortic balloon valvuloplasty if indicated. Modern cancer treatments associated with improved
long-term prognosis may allow the appropriate cure of aortic stenosis.
Summary We discuss the protocol, outcomes, and evolving recommendations of aortic valve replacement in cancer patients with
aortic stenosis.
Keywords Aortic stenosis . Cancer . Cardio-oncology . Interventional cardiology . Surgical aortic valve replacement .
Transcatheter aortic valve replacement
Introduction
The prevalence of heart valve calcifications increases with age
[1] and their presence is associated with a poor prognosis [2].
Calcific aortic stenosis (AS) is a common condition of the
elderly [3], caused by progressive atherosclerosis and struc-
tural valve degeneration due to inflammation, fibrosis, and
calcification related to traditional cardiovascular risk factors
[4]. The latter is the main driver of atherosclerotic cardiovas-
cular disease in elderly populations [5]. Cancer also occurs
more frequently with advancing age [6] and has a major im-
pact on mortality. In the Atherosclerosis Risk in Communities
(ARIC) Trial, the presence of ideal cardiovascular health
markers in midlife (smoking, body mass index, total choles-
terol, blood pressure, physical activity, and blood glucose)
was associated with a lower incidence of both AS and cancer
after 75 years of age [4, 7]. These results highlight not only the
age-dependency, but also common predisposing factors for
cancer and cardiovascular disease.
The elderly are at risk for both cardiovascular disease, ei-
ther ischemic or valvular, and cancer. The simultaneous diag-
nosis of both these conditions in the same patient, which is a
frequent occurrence [8], raises difficult treatment decisions.
The treatment of the underlying cardiovascular disease pro-
cess may lead to cancer-associated risks (such as bleeding)
[9], while cancer therapies may lead to cardiac complications
and worsen cardiovascular outcomes [10, 11].
Of all cardiovascular comorbidities in cancer patients, AS
is one of the most important comorbidities. Surprisingly, no
large-scale epidemiological studies currently report the exact
prevalence of AS in cancer patients. The standard treatment is
still surgical aortic valve replacement (SAVR), although the
cancer patient is often a high-risk candidate for major cardiac
surgery. Transcatheter aortic valve replacement (TAVR) was
introduced in clinical practice to potentially benefit such pa-
tients, which are considered too high risk for SAVR [12].
Today, it is commercially available for patients with symptom-
atic AS at high and intermediate risk for traditional surgery.
Very recently, the PARTNER 3 trial identified a survival ben-
efit of TAVR over SAVR at 1-year in low-risk patients [13].
This conclusion is supported by the EVOLUT trial in low-risk
patients, suggesting that TAVR was non-inferior to SAVR at
24 months [14]. Current research trials are investigating
TAVR for asymptomatic patients as well. The current review
considers the available data on the association between AS,
cancer, and therapeutic options (Table 1) in this increasingly
identified patient population, with emphasis on endovascular
procedures.
Aortic Stenosis Prevalence and Prognosis
in Cancer Patients
In the General Cancer Population
The prevalence of cancer in patients with severe AS varies
between 5.4 and 26% [24, 28]. There are very few reports
regarding the prognosis of patients with valvular disease and
cancer, and even less are available in patients with AS. In a 10-
year single-center retrospective study, cancer patients with se-
vere AS and amean aortic valve area 1.0 ± 0.3 cm2 had a 5-year
mortality of 48% [29]. Most deaths (59%) were due to cancer
progression, but 31% were due to heart failure and stroke.
Interestingly, the prevalence of AS was relatively low (111
cases from 26,325 cancer patients, 0.42%), despite a mean
age of 79.8 years of the whole studied population. Older age
and symptomatic AS (syncope or heart failure) were among the
main independent predictors of mortality. Mortality due to heart
failure was more frequently encountered in patients with AS
than in cancer patients without aortic valve disease.
A Japanese retrospective study of 3815 patients in a multi-
center AS registry found that outcomes are worse not only in
patients with active cancer but also in those with a history of
malignancy [25•]. Mortality was mainly cancer-related, with
comparable aortic valve–related deaths between cancer and
no-cancer patients.
In Patients with Previous Chest Radiotherapy
Chest irradiation used to treat thoracic cancers, such as lym-
phomas, is responsible for chronic pericarditis, coronary ar-
tery disease, myocardial fibrosis, and restrictive physiology,
but also for valve disease including AS [30–32]. The preva-
lence of AS reaches 16% at 20 years after radiation therapy
[33]. This is due to the osteogenic transformation of aortic
valve interstitial cells, presumably involved in the
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pathogenesis of calcific AS [34]. The rate of moderate AS
progression in patients with previous mediastinal irradiation
is the same as that of matched control patients: 60% of both
groups progress to symptomatic severe AS at a mean of 3.6 ±
2 years of follow-up [23]. Symptoms attributable to AS occur
earlier in patients with a history of chest radiation therapy,
which increase referral for AVR. In the PARTNER trial, ap-
proximately 5% of the enrolled patients had a history of ther-
apeutic thoracic irradiation [35]. Chest radiation therapy may
induce mediastinal fibrosis and “porcelain aorta” that makes
SAVR very difficult (“hostile thorax”). In patients who have
achieved remission, TAVR is an appropriate therapy [19, 33,
36]. The risk of valvular disease with cancer therapy depends
on radiation dose, concomitant chemotherapy, and duration
from first exposure [37, 38]. Among all chemotherapeutic
agents, anthracyclines accelerate valve fibrosis, mainly of
the left heart [30, 39]. Literature data regarding specific can-
cers and aortic valve disease is missing.
Cancer as an Incidental Finding During TAVR
Assessment
Cancer is sometimes found during the cardiovascular assess-
ment preceding planned TAVR. In a single-center report on
394 patients assessed for TAVR, multi-slice computed tomog-
raphy (CT) identified malignant findings in 4.2% of patients
[40]. Similar results were reported in 131 TAVR candidates
with a mean age of 81.6 years. Thoraco-abdominal CT angi-
ography, which is performed for vascular anatomy imaging
for procedural preplanning, identified masses highly suspi-
cious for malignancy in 3.8% of the studied group [41]. In
another single-center trial on 484 consecutive patients evalu-
ated for TAVR, solitary pulmonary nodules larger than 5 mm
were found by CTangiography in 87 patients (18%) [42]; at a
median follow-up of 455 days, cancer was confirmed in just 2
patients. The incidental discovery of non-definite cancer lung
nodules should prompt an expedited lung nodule workup. The
decision for TAVR versus open heart surgery is based on the
definite diagnosis of cancer, location and size of nodule, need
for surgery, and overall prognosis. This is not the case for
patients with a definite diagnosis of thoracic malignancy,
where a multidisciplinary Tumor Board evaluation should es-
tablish future diagnostic work-up and treatment.
Aortic valve calcification can also be incidentally detected
when low-dose CT is used to screen for cancer, identifying AS
when the aortic valve calcium score is higher than 138.37 [43].
SAVR in Cancer Patients
Patients with severe AS are poor candidates for surgery main-
ly because of comorbidities that increase the estimated
periprocedural morbidity and mortality. However, patients
with cancer in early stages with symptomatic AS or an aortic
valve area under 0.75 cm2 should be considered for AVR [29].
Occasional reports describe SAVR being performed prior to
cancer surgery, yielding various results [43].
An important issue related to SAVR in cancer patients is
that valve surgery requires extracorporeal circulation. Among
various other systemic effects, cardio-pulmonary bypass may
induce immunosuppression, increase inflammation (as dem-
onstrated by a significant increase in TNF-alpha, Il-10, Il-6, Il-
1, and TGF-beta) [44], and worsen cancer outcomes [45].
Because of the immunosuppressive effects, patients with he-
matological cancers may have worse outcomes than those
with solid tumors and better functioning immune system.
Old reports on small patient cohorts found an increased risk
of metastasis in the early stages of lung cancer (I and II) [46],
possibly related to the significant immunosuppression in-
duced by the dampening of T cell–mediated response by
TGF-beta [44]. Some small trials that investigated the out-
come of major cardio-thoracic surgery excluded stage IV sub-
jects and did not confirm the worsening of cancer prognosis,
but reported higher periprocedural mortality [46]. No major
influence on cancer-related outcome was observed in patients
having a mean survival of 4.3 years if their AS was not surgi-
cally repaired and 5.8 years if it was surgically repaired [46].
In another small retrospective trial, SAVR provided a survival
benefit in patients with severe AS irrespective of cancer status
or the presence of metastatic disease [16••].
All these small trials suggest that cardio-pulmonary bypass
needed for valve surgery may be used in cancer patients in
early stages of the disease, prior to specific cancer treatment
and irrespective of cancer type, including hematological neo-
plasms [47–49].
In patients with coronary artery disease, off-pump coronary
artery bypass grafting (CABG) provides the same outcome as
on-pump procedures in oncologic patients [47]. However, a
large retrospective study performed on 43,347 patients treated
by CABG with or without cardio-pulmonary bypass demon-
strated a 12% increase in cancer mortality [50]. Among 11
different types of cancer, melanoma and lung cancer were
associated with higher surgical risk when cardio-pulmonary
bypass was performed (66% and 36% respectively versus off-
pump surgery). Cardio-pulmonary bypass was indicated
mainly for CABG, with very few patients undergoing surgery
for valvular heart disease and AS in all the reported studies
above.
In a trial performed on 89 cancer patients from different
locations, the patients were operated under extracorporeal cir-
culation; 45% had active cancer and were treated by SAVR
[15]. Although perioperative morbidity and mortality were not
different in cancer versus non-cancer patients, long-term sur-
vival was reduced in the active cancer subgroup because of
cancer complications.
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It is reasonable to assume that TAVR may provide better
outcomes than SAVR in cancer patients with severe AS by
avoiding cardio-pulmonary bypass. This hypothesis, however,
has not yet been tested in a prospective randomized trial.
TAVR in Cancer Patients
The major therapeutic conundrum in cancer patients with AS
is that they are often ineligible for valve replacement because
of cancer and cannot undergo cancer surgery because of se-
vere valve disease. If one includes active cancer as a major
comorbidity that makes surgical risk prohibitive, then TAVR
would be indicated. TAVR may be an acceptable-risk inter-
vention for the treatment of AS and may allow patients to
undergo cancer treatment as indicated [9]. In the original
PARTNER trial report, 1-year mortality in patients with severe
symptomatic AS randomized to optimal medical therapy
reached 50.7% [12]. In the PARTNER trial, risk factors for
death included the history of cancer (HR 2.4; 68% CI 1.7–3.2)
along with a smaller body frame, lower albumin levels, and
prosthesis mismatch [51]. Cancer was diagnosed in 14% (47
out of 310) of the patients enrolled in this trial.
Patients with AS are considered high-risk for SAVR be-
cause of surgical challenges (i.e., porcelain aorta) or major
comorbidities, including cancer. Technical difficulties for sur-
gery may be overcome by TAVR [36], but major comorbidi-
ties may influence post-TAVR prognosis just as with SAVR
[51]. To qualify for TAVR, patients should have a prognosis of
1 year or greater [22]. However, accurately estimating prog-
nosis is often difficult in this patient population, especially
given the rapidly expanding therapies for cancer. In addition,
it should be taken into consideration that cancer patients with
AS may need a valve intervention in different stages of their
neoplastic disease. Patients with already-treated cancers who
are in remission are often eligible for TAVR [52]. In these
cases, remission should be evaluated and confirmed by the
oncology team before referring the patient to the catheteriza-
tion lab.
The management of valvular heart disease is most difficult
to decide in patients with a concomitant diagnosis of severe
AS and cancer. Patients with a cancer diagnosis in early stages
who can safely receive oncologic treatment could be easily
considered for TAVR as soon as remission is confirmed. In
other cases, performing TAVR first allows for radical onco-
logic surgical treatment shortly after valve intervention
[53–55]. Patients with AS and a localized cancer complication
(e.g., bleeding from colon adenocarcinoma) can be stabilized
and TAVR can be considered after exclusion of metastatic
disease. A small study of 65 cancer patients with severe AS
found that AVR improves survival, regardless of the type of
cancer or anti-cancer therapy, with TAVR being the most ben-
eficial [26].
The difference in outcomes for patients with cancer and
active disease versus those in remission was demonstrated
recently in a registry that included 1821 subjects treated by
TAVR [24]. Ninety-nine patients (5.4%) had different types of
active cancer, while 251 patients had a history of treated can-
cers, currently in remission. One-year mortality was highest in
patients treated by TAVR who also had active cancers versus
those with cancers in remission (37.4% versus 16.4% respec-
tively). Thirty-day mortality was the same between the sub-
groups, irrespective of cancer stage, cancer history, or cancer
absence. The best 3-year outcome was observed in known,
slowly progressing cancers, such as prostate neoplasia or
chronic lymphocytic leukemia. It should be noted that the
worst prognosis was observed in cancer patients undergoing
TAVR before having their cancer treated by specific oncologic
therapy. TAVR patients that needed a specific cancer treatment
in the first 12 months after the valvular intervention had a
higher mortality than patients in true remission [22].
Patients with advanced, stage IV, metastatic disease, with
severe anemia, symptomatic heart failure, and a very short
estimated survival could be offered balloon valvuloplasty as
a “bridge-to-destination” intervention [56]. In these final dis-
ease stages, a more conservative approach toward improving
quality of life during palliative treatment for the oncologic
disease is preferred. In this type of scenario, there is a limited
evidence base, as data are mainly derived from case reports
and case series. The futility of costly and potentially danger-
ous interventions like TAVR should be established by a mul-
tidisciplinary team consisting of both the oncologist, the car-
diologist, and the palliative care team [57].
In the OCEAN-TAVI registry that included 749 patients
treated by TAVR, 47 patients had an active neoplastic disease
of various types [21]; the Society of Thoracic Surgery (STS)
and EuroSCORE II risk scores were lower in the cancer sub-
group. Periprocedural complications and 30-day survival were
similar in patients with versus without cancer. Late mortality
(> 30-day post-TAVR) was 7% and was predicted by the pres-
ence of metastatic disease at the time of intervention with a
hazard ratio of 4.73 (95% CI 1.12–20.0; p = 0.035). Late mor-
tality in the cancer TAVR subgroup was 10.6% versus 6.4% in
the non-cancer subgroup.
Data from the TOP-AS registry were recently published
[27••]. The study included 222 cancer patients, of which
40% had stage IV cancer at the time of TAVR, and 2522
non-cancer patients. As with the OCEAN-TAVI registry, 30-
day mortality was comparable between the groups. One-year
mortality was higher in the cancer group (15%, of which half
were cancer-related, versus 9% in the non-cancer group).
Stage I and stage II cancer patients had similar outcomes to
non-cancer patients, whereas those with progressive or stage
III and IV malignancies had significantly worse survival.
A recent issue of biological transcatheter and surgically
implanted valves related to subclinical leaflet thrombosis with
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increased transvalvular gradients [58] may also occur in on-
cologic patients due to coagulation anomalies. Until further
data will become available specifically for cancer patients,
systemic anticoagulation should be given as the only treat-
ment proven to control or reduce valve thrombosis [59].
Patients with radiation-induced AS are younger and have
lower STS scores and better prognoses after TAVR than pa-
tients with calcific AS [18]. When accepting cancer patients
with a history of chest irradiation and calcified ascending
aorta for TAVR, the risk of perforation or annular rupture
should be considered [60]. A small series of non-
randomized patients with previous Hodgkin disease with
radiation-induced AS demonstrated similar results for
TAVR compared to SAVR [19]. Long-term mortality in pa-
tients with previous chest radiation therapy was higher than
expected after SAVR and can reach up to 55% at a mean
follow-up of 7.6 years [17].
A recent expert consensus issued by the Society for
Cardiovascular Angiography and Interventions recommends
aortic balloon valvuloplasty or TAVR for cancer patients with
AS either as palliation or cure for the valve disease, as indi-
cated, to improve the quality of life or to facilitate appropriate
cancer therapy [61]. Again, given the nature of this patient
population, large trials are difficult to conduct, limiting the
quality of the data supporting this approach.
Frailty, defined as the age-related diminished capability to
recover from pathologic or iatrogenic stressors [62], is an es-
sential parameter when deciding between TAVR and SAVR in
the general population. This parameter becomes of great in-
terest in cancer patients, who can be frail due to their cancer
treatments, despite having a favorable oncologic prognosis
[63, 64]. Although there are multiple instruments that can be
used to measure frailty and this parameter has been related to
increased post-AVR mortality [65, 66], there are no guideline
recommendations regarding frailty and TAVR or SAVR in
cancer patients. General recommendations to assess physical
performance, disability regarding activities of daily living,
cognitive function, hemoglobin, and albumin as part of the
evaluation of older adults with severe AS [66–68] can be
considered in cancer patients as well. The FRAILTY-AVR
study, one of the largest studies evaluating the impact of frailty
indices in patients undergoing TAVR and SAVR, included 151
(15%) patients with cancer [67]. Although the study found
increased 1-year mortality in frail patients, the result was not
statistically significant in the cancer subgroup (adjusted OR of
1.31, CI 0.79–2.19). The Essential Frailty Toolset (EFT) eval-
uating 4 simple parameters (i.e., chair rises, cognitive impair-
ment, hemoglobin, and serum albumin) was the measurement
tool for frailty best associated with 1-year mortality. The au-
thors recommend EFT use for identifying vulnerable patients
before TAVR and SAVR in order to better target pre- or
postprocedural interventions to improve outcomes [67].
TAVR and Cancer: What Do the Current
Guidelines Say?
In the European guidelines released in 2017, aortic valve re-
placement is indicated in patients with symptomatic severe AS
in the “absence of comorbidity or general condition that make
benefit unlikely” [69]. In these cases, medical treatment is
preferred. When the medical team agrees upon the benefit of
the procedure, the patient may be treated by TAVR or SAVR,
depending on the pre-procedural calculated risk [69]. The
same decision is stated in the 2017 AHA/ACC Focused
Update for the management of valvular heart disease: TAVR
is recommended in severe symptomatic AS (stage D of
Fig. 1 Proposed algorithm for the
management of severe
symptomatic aortic stenosis in
cancer patients. SAVR, surgical
aortic valve replacement; TAVR,
transcatheter aortic valve
replacement
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disease) when the patient has a prohibitive risk for SAVR and
when anticipated survival is greater than 12 months [70].
Despite guideline recommendations, most cancer patients
today have much better prognoses and survive for more than
12 months. Thus, most of the cancer patients excluded from
randomized trials up-to-date could benefit from valve inter-
vention to improve quality of life and likely even survival.
AS Treatment in Cancer Patients: Final
Considerations
Randomized trials focused on the outcome are drastically
needed in cancer patients with AS, depending on cancer type
and stage of the neoplastic disease. Early-stage cancers may
benefit fromAS treatment just as non-cancer patients since the
outcomes of most cancer types are significantly improved
with modern therapy (i.e., surgical, chemo-, immuno-, and/
or radiotherapy).
The optimal treatment approach is not well established and
should be decided on a case-by-case basis: valve disease or
cancer, which should be treated first? We propose an algo-
rithm for the management of aortic stenosis in cancer patients
in Fig. 1. In terminal patients with cancer and severe AS, a
“bridge-to-destination” treatment such as balloon
valvuloplasty can be considered as part of the palliative care,
in selected cases.
When caring for patients with gastrointestinal cancers that
are not already cured or appropriately treated, the medical
team should be alert and attempt to prevent bleeding compli-
cations of antithrombotic cardiac therapies.
Due to the minimally invasive nature of TAVR compared
to SAVR, TAVR should be preferred in cancer patients as it
offers similar 5-year outcomes. In patients with a remote his-
tory of cancer and radiation-induced AS, TAVR is by far the
most useful intervention, especially in the presence of a “hos-
tile thorax.”
SAVR, TAVR, or balloon valvuloplasty in cancer patients
with concomitant AS should be decided on a case-by-case
basis depending on cancer stage and associated treatment,
expected outcome, and frailty.
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